2020 Mar 9;11(1):1272
This approval marked the first oral GLP-1 RA indicated specifically for obesity, creating a new option for patients and clinicians who prefer or require non-injectable therapies, in contrast to Rybelsus, an oral semaglutide approved for the treatment of type 2 diabetes
The median follow-up duration was 1 year (IQR: 0.52 years), with key findings including a median weight loss of 11.7 kg and a median BMI at the most recent follow-up of 31.2 kg/m 2 , reflecting a median reduction of 3.7 kg/m 2
What is the best weight-loss goal: fat loss or total weight loss
And when your blood sugar gets low enough, your body ratchets up a process called glycogenesis, which breaks down tissue, including fat, to maintain blood sugar
Areas where research is still evolving Doctors still do not fully know: Long-term muscle effects after years of use Risks in older patients Effects in patients with frailty or sarcopenia Whether different GLP-1 drugs affect the muscle differently This is an active area of obesity medicine research
